Navigation

Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]

Erlotinib, in combination with bevacizumab for the second line treatment of non-squamous advanced or metastatic non-small-cell lung cancer after previous platinum containing chemotherapy

Status: Suspended
Expected date of issue: TBC
Referral date: November 2008
Process: STA
Topic area:
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Sally Gallaugher
Communications manager: Alice Law
Assessment Group / Evidence Review Group: Liverpool Reviews and Implementation Group
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
2 July 2009 Appraisal suspended.

6 July 2009

 

The manufacturer of erlotinib has advised us that regulatory approval for this technology is not being sought. The Institute has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes

Top


 

Key documents

This page was last updated: 04 July 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.